I agree that this site is using cookies. You can find further informations here.
X
Długosz-Danecka, M.
~ 0  results:
Search for persons X
?
1

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERAT..:

Le Gouill, S. ; Długosz-Danecka, M. ; Rule, S....
HemaSphere.  6 (2022)  - p. 1021-1022 , 2022
Link: https://doi.org/10.1097/..
 
?
2

Brentuximab vedotin with chemotherapy for stage III/IV clas..:

Straus D. J ; Dlugosz-Danecka M ; Alekseev S...
info:eu-repo/semantics/altIdentifier/wos/WOS:000523314100008.  , 2020
Link: http://hdl.handle.net/11..
 
?
3

Durable response with single-agent acalabrutinib in patient..:

Wang, M ; Rule, S ; Zinzani, PL...
Wang , M , Rule , S , Zinzani , PL , Goy , A , Casasnovas , O , Smith , SD , Damaj , G , Doorduijn , J , Lamy , T , Morschhauser , F , Panizo , C , Shah , B , Davies , A , Eek , R , Dupuis , J , Jacobsen , E , Kater , AP , Le Gouill , S , Oberic , L , Robak , T , Jain , P , Frigault , MM , Izumi , R , Nguyen , D , Patel , P , Yin , M & Dlugosz-Danecka , M 2019 , ' Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma ' , Leukemia , vol. 33 , no. 11 , pp. 2762-2766 . https://doi.org/10.1038/s41375-019-0575-9.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
4

Durable response with single-agent acalabrutinib in patient..:

Wang, M ; Rule, S ; Zinzani, PL...
https://pure.eur.nl/en/publications/6952abb3-6f36-4ed2-a1fe-2b64b1b41597.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
5

Ibrutinib does not have clinically relevant interactions wi..:

Jong, J. (Jan) de ; Mitselos, A. (Anna) ; Jurczak, W. (Wojciech)...
https://hdl.handle.net/10171/66333.  , 2020
Link: https://hdl.handle.net/1..
 
?
6

Durable response with single-agent acalabrutinib in patient..:

Wang, M. (Michael) ; Rule, S. (Simon) ; Zinzani, P.L. (Pier Luigi)...
http://repub.eur.nl/pub/120623.  , 2019
Link: http://repub.eur.nl/pub/..
 
?
7

Durable response with single-agent acalabrutinib in patient..:

Wang, M. (Michael) ; Rule, S. (Simon) ; Zinzani, P.L. (P. L.)...
https://hdl.handle.net/10171/62620.  , 2019
Link: https://hdl.handle.net/1..
 
?
8

The PD-1- and LAG-3-targeting bispecific molecule tebotelim..:

Luke, Jason J. ; Patel, Manish R. ; Blumenschein, George R....
Nature Medicine.  29 (2023)  11 - p. 2814-2824 , 2023
Link: https://doi.org/10.1038/..
 
?
9

Poster: HL-147: Brentuximab Vedotin with Chemotherapy for P..:

Ramchandren, Radhakrishnan ; Długosz-Danecka, Monika ; Connors, Joseph M....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S236 , 2021
Link: https://doi.org/10.1016/..
 
?
10

Older patients (aged ≥60 years) with previously untreated a..:

Evens, Andrew M. ; Connors, Joseph M. ; Younes, Anas...
Haematologica.  107 (2021)  5 - p. 1086-1094 , 2021
Link: https://doi.org/10.3324/..
 
?
11

Efficacy of high-dose corticosteroid-based treatment for ch..:

Puła, Bartosz ; Długosz-Danecka, Monika ; Salomon-Perzyński, Aleksander...
Advances in Medical Sciences.  65 (2020)  2 - p. 371-377 , 2020
Link: https://doi.org/10.1016/..
 
?
12

Durable response with single-agent acalabrutinib in patient..:

Wang, Michael ; Rule, Simon ; Zinzani, Pier Luigi...
Leukemia.  33 (2019)  11 - p. 2762-2766 , 2019
Link: https://doi.org/10.1038/..
 
?
13

Genetic heterogeneity in primary and relapsed mantle cell l..:

Wu, Chenglin ; de Miranda, Noel FCC ; Chen, Longyun...
Oncotarget.  7 (2016)  25 - p. 38180-38190 , 2016
Link: https://doi.org/10.18632..
 
?
14

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERAT..:

S. Le Gouill ; M. Długosz-Danecka ; S. Rule...
http://journals.lww.com/10.1097/01.HS9.0000847392.35657.0d.  , 2022
Link: https://doi.org/10.1097/..
 
?
15

A practical approach to the 2022 ESC cardio-oncology guidel..:

Leszek, Przemysław ; Klotzka, Aneta ; Bartuś, Stanisław...
https://journals.viamedica.pl/kardiologia_polska/article/view/96840.  , 2023
Link: https://journals.viamedi..
 
1-15